Valuation: Indivior Pharmaceuticals, Inc.

Market Cap 4.9B 4.29B 3.96B 3.66B 6.89B 471B 7.02B 47.25B 18.54B 231B 18.42B 18.02B 794B P/E 2026 *
12.7x
P/E 2027 * 11.1x
Enterprise Value 4.96B 4.33B 4.01B 3.7B 6.97B 476B 7.1B 47.78B 18.75B 233B 18.63B 18.22B 803B EV / Sales 2026 *
3.94x
EV / Sales 2027 * 3.44x
Free-Float
97.22%
Yield 2026 *
-
Yield 2027 * -
1 week+5.27%
1 month+20.78%
3 months+60.36%
6 months+29.91%
Current year+20.90%
1 week 1,160
Extreme 1160
1,264
1 month 975.5
Extreme 975.5
1,264
3 years 554.83
Extreme 554.83
2,020
5 years 335
Extreme 335
2,020
Change 5-day change 1-year change 3-year change Capi.($)
+1.56%+5.27%+49.52%-20.18% 4.9B
-2.48%-6.72%+44.19%+156.43% 1,054B
-1.52%-5.01%+61.87%+58.79% 621B
-1.30%-3.88%+27.81%+79.97% 438B
-1.12%-3.68%+26.89%+20.58% 325B
-1.73%-3.45%+26.95%+44.09% 281B
-1.95%-13.92%+15.96%+19.76% 262B
-1.45%-2.37%-27.87%-39.87% 219B
-1.44%-3.49%+19.60%+56.20% 195B
-1.04%-4.63%+16.01%+68.47% 163B
Average -1.24%-4.15%+26.09%+44.42% 395.13B
Weighted average by Cap. -0.90%-4.77%+33.19%+76.91%

Financials

2026 *2027 *
Net sales 1.26B 1.1B 1.02B 939M 1.77B 121B 1.8B 12.12B 4.75B 59.16B 4.72B 4.62B 204B 1.31B 1.14B 1.06B 976M 1.84B 126B 1.87B 12.6B 4.94B 61.51B 4.91B 4.8B 212B
Net income 414M 362M 335M 309M 583M 39.81B 593M 3.99B 1.57B 19.49B 1.56B 1.52B 67.12B 473M 413M 382M 353M 665M 45.42B 677M 4.56B 1.79B 22.24B 1.78B 1.74B 76.58B
Net Debt 54.5M 47.63M 44.03M 40.68M 76.6M 5.23B 77.99M 525M 206M 2.56B 205M 200M 8.83B -403M -353M -326M -301M -567M -38.75B -577M -3.89B -1.52B -18.97B -1.52B -1.48B -65.33B
Logo Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
40.23USD
Average target price
50.83USD
Spread / Average Target
+26.36%

Quarterly revenue - Rate of surprise